Key result
Mean pulmonary arterial blood flow velocity during peak hyperemia correlated significantly with invasive, non-invasive, and clinical prognostic parameters at baseline and follow-up.
Why the study?
Does meanPAvel during peak hyperemia correlate with established prognostic surrogate markers in patients with pulmonary vascular disease?
Cohort (n=20)
No
Does meanPAvel during peak hyperemia correlate with established prognostic surrogate markers in patients with pulmonary vascular disease?
Effect estimate: R2 > 0.30
p-value: p=<0.05
Mean pulmonary arterial blood flow velocity during peak hyperemia measured by CMR correlates with established prognostic markers in pulmonary vascular disease, suggesting its potential as a non-invasive marker of disease progression.
May support CMR meanPAvel as non-invasive marker in pulmonary vascular disease; hypothesis-generating, requires prospective validation.
No unified method exists to effectively predict and monitor progression of pulmonary arterial hypertension (PAH). We assessed the longitudinal relationship between a novel marker of cardiopulmonary reserve and established prognostic surrogate markers in patients with pulmonary vascular disease. Twenty participants with confirmed (n = 14) or at high risk (n = 6) for PAH underwent cardiovascular magnetic resonance (CMR) at baseline and after ~6 months of guideline-appropriate management. Ten PAH participants underwent RHC within 48 h of each CMR. RHC (mean pulmonary arterial pressure, mPAP; pulmonary vascular resistance index, PVRI; cardiac index, CI) and phase-contrast CMR (mean pulmonary arterial blood flow velocity, meanPAvel) measurements were taken at rest and during continuous adenosine infusion (70/140/210 mcg/kg/min). Initial meanPAvel’s (rest and hyperemic) were correlated with validated surrogate prognostic parameters (CMR: RV ejection fraction, RVEF; RV end systolic volume indexed, RVESVI; RHC: PVRI, CI; biomarker: NT-pro brain natriuretic peptide, NTpBNP; clinical: 6-min walk distance, 6MWD), a measure of pulmonary arterial stiffness (elastic modulus) and volumetric estimation of RV ventriculoarterial (VA) coupling. Changes in meanPAvel’s were correlated with changes in comparator parameters over time. At initial assessment, meanPAvel at rest correlated significantly with PVRI (inversely), CI (positively) and elastic modulus (inversely) (R 2 > 0.37,P < 0.05 for all), whereas meanPAvel at peak hyperemia correlated significantly with PVRI, RVEF, RVESVI, 6MWD, elastic modulus and VA coupling (R 2 > 0.30,P < 0.05 for all). Neither resting or hyperemia-derived meanPAvel correlated with NTpBNP levels. Initial meanPAvel at rest correlated significantly with RVEF, RVESVI, CI and VA coupling at follow up assessment (R 2 > 0.2,P < 0.05 for all) and initial meanPAvel at peak hyperemia correlated with RVEF, RVESVI, PVRI and VA coupling (R 2 > 0.37,P < 0.05 for all). Change in meanPAvel at rest over time did not show statistically significant correlation with change in prognostic parameters, while change in meanPAvel at peak hyperemia did show a significant relationship with ΔRVEF, ΔRVESVI, ΔNTpBNP and ΔCI (R 2 > 0.24,P < 0.05 for all). MeanPAvel during peak hyperemia correlated with invasive, non-invasive and clinical prognostic parameters at different time points. Further studies with predefined clinical endpoints are required to evaluated if this novel tool is a marker of disease progression in patients with pulmonary vascular disease.
No takes yet. Share an insight, caveat, or question.
Baillie et al. (2016) conducted a cohort in Pulmonary vascular disease (PAH or high risk for PAH) (n=20). Mean pulmonary arterial blood flow velocity (meanPAvel) during peak hyperemia vs. meanPAvel at rest was evaluated on Correlation of initial meanPAvel at peak hyperemia with surrogate prognostic parameters (PVRI, RVEF, RVESVI, 6MWD, elastic modulus, VA coupling) (R2 > 0.30, p=<0.05). Mean pulmonary arterial blood flow velocity during peak hyperemia correlated significantly with invasive, non-invasive, and clinical prognostic parameters at baseline and follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: